A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterationsMargaret C. Wheless, Kristen K. Ciombor, Joleen M. Hubbard et al.|The Oncologist|2025Cited by 3